PriceTargets.com logo

NASDAQ:CDAK - Codiak BioSciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.00
  • Forecasted Upside: 106.47 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$14.53 As of 10/22/2021 01:00 AM ET
▼ -0.55 (-3.65%)

This chart shows the closing price for CDAK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Codiak BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDAK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDAK

Analyst Price Target is $30.00
▲ +106.47% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Codiak BioSciences in the last 3 months. The average price target is $30.00, with a high forecast of $31.00 and a low forecast of $29.00. The average price target represents a 106.47% upside from the last price of $14.53.

This chart shows the closing price for CDAK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Codiak BioSciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2021William BlairReiterated RatingBuyMedium
12/31/2020WedbushBoost Price TargetPositive ➝ Outperform$19.00 ➝ $31.00N/A
11/9/2020William BlairReiterated RatingOutperformLow
11/9/2020WedbushInitiated CoverageOutperform$19.00High
11/8/2020The Goldman Sachs GroupInitiated CoverageBuy$29.00High
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/24/2021

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Codiak BioSciences logo
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $14.53
Low: $14.33
High: $15.11

50 Day Range

MA: $17.31
Low: $13.97
High: $20.63

52 Week Range

Now: $14.53
Low: $7.90
High: $37.85

Volume

26,947 shs

Average Volume

147,799 shs

Market Capitalization

$324.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Codiak BioSciences?

The following equities research analysts have issued reports on Codiak BioSciences in the last twelve months: The Goldman Sachs Group, Inc., Wedbush, William Blair, and Zacks Investment Research.
View the latest analyst ratings for CDAK.

What is the current price target for Codiak BioSciences?

2 Wall Street analysts have set twelve-month price targets for Codiak BioSciences in the last year. Their average twelve-month price target is $30.00, suggesting a possible upside of 106.5%. Wedbush has the highest price target set, predicting CDAK will reach $31.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $29.00 for Codiak BioSciences in the next year.
View the latest price targets for CDAK.

What is the current consensus analyst rating for Codiak BioSciences?

Codiak BioSciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDAK will outperform the market and that investors should add to their positions of Codiak BioSciences.
View the latest ratings for CDAK.

What other companies compete with Codiak BioSciences?

Other companies that are similar to Codiak BioSciences include Coherus BioSciences, Caribou Biosciences, Sangamo Therapeutics, Krystal Biotech, Vaxcyte, Century Therapeutics, Monte Rosa Therapeutics, Omega Therapeutics, Icosavax, Cullinan Oncology, BioAtla, iTeos Therapeutics, MeiraGTx, Immunovant and Agenus.

How do I contact Codiak BioSciences' investor relations team?

The company's listed phone number is 617-949-4100 and its investor relations email address is [email protected] The official website for Codiak BioSciences is www.codiakbio.com.